Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Change in Accured Expenses (2010 - 2026)

Exelixis (EXEL) posted quarterly Change in Accured Expenses of $4.0 million for Q2 2026, down 12.18% year-over-year from $4.6 million in Q2 2025, and up 1039.15% quarter-over-quarter from $355000.0 in Q1 2026.

Analysis

Exelixis (EXEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Exelixis' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $4.0 million for Q2 2026.

  • In Q2 2026, Change in Accured Expenses fell 12.18% year-over-year to $4.0 million; the TTM figure through Apr 2026 stood at $1.3 million (down 83.85% YoY), while the FY2026 annual figure was $1.9 million, up 1374.5% from the prior year.
  • Change in Accured Expenses for Q2 2026 stood at $4.0 million, up from $355000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.1 million in Q2 2023, with the low at -$54.3 million in Q2 2022.
  • The 5-year median for Change in Accured Expenses is $604500.0 (2025), against an average of -$3.4 million.
  • The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 5499.1% in 2022, then jumped 223.48% in 2025.
  • Exelixis' Change in Accured Expenses stood at -$54.3 million in 2022, then surged by 100.49% to $264000.0 in 2023, then soared by 410.23% to $1.3 million in 2024, then sank by 32.96% to $903000.0 in 2025, then surged by 347.84% to $4.0 million in 2026.
  • Business Quant data shows EXEL's Change in Accured Expenses at $4.0 million in Q2 2026, $355000.0 in Q1 2026, and $903000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 11.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 55.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 212.44 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 61.62 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 68.82 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -9.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 -9.31 Mn
Apr 3, 2026 4.04 Mn
Jan 2, 2026 355,000.00
Oct 3, 2025 903,000.00
Jul 4, 2025 -3.96 Mn
Apr 4, 2025 4.61 Mn
Jan 3, 2025 854,000.00
Sep 27, 2024 1.35 Mn
Jun 28, 2024 1.48 Mn
Mar 29, 2024 -3.83 Mn
Dec 29, 2023 264,000.00
Sep 29, 2023 -2.19 Mn
Jun 30, 2023 5.14 Mn
Mar 31, 2023 -1.86 Mn
Apr 1, 2022 -54.26 Mn
Apr 2, 2021 1.01 Mn
Jan 1, 2021 -15.34 Mn
Sep 27, 2019 23.94 Mn
Jun 28, 2019 -29.17 Mn
Mar 29, 2019 21.17 Mn